Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy

Abstract

Gene-directed enzyme prodrug therapy (GDEPT) has been intensively studied as a promising new strategy of prodrug delivery, with its main advantages being represented by an enhanced efficacy and a reduced off-target toxicity of the active drug. In recent years, numerous therapeutic systems based on GDEPT strategy have entered clinical trials. In order to deliver the desired gene at a specific site of action, this therapeutic approach uses vectors divided in two major categories, viral vectors and non-viral vectors, with the latter being represented by chemical delivery agents. There is considerable interest in the development of non-viral vectors due to their decreased immunogenicity, higher specificity, ease of synthesis and greater flexibility for subsequent modulations. Dendrimers used as delivery vehicles offer many advantages, such as: nanoscale size, precise molecular weight, increased solubility, high load capacity, high bioavailability and low immunogenicity. The aim of the present work was to provide a comprehensive overview of the recent advances regarding the use of dendrimers as non-viral carriers in the GDEPT therapy.

Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment—An Overview

“…Dendrimers can be used as delivery vectors for genetic material ( Figure 4 ). They can transfer DNA or RNA molecules for cancer treatment [ 195 , 196 ]. PAMAM dendrimers with amino end groups can interact with the phosphate groups in nucleic acid molecules, forming complexes that will be directed to tumors and allow the transfer of genetic material through endocytosis into cancer cells and then into their nuclei [ 51 , 56 , 101 , 197 , 198 , 199 ].…”

Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance

“…T-DM1 has low payload membrane permeability and is bound by a thioether non-cleavable linker, while T-DXd has high payload membrane permeability and is bound by a cleavable tetrapeptide-based linker. Between the two, only T-DXd presents the bystander effect [24] that leads to cell death of the neighboring tumor cells by amplifying the activity of the cytotoxic drug [25] (Figure 2b). Regarding their efficiency, a study performed by Cortes et al showed that the risk of disease progression or death was reduced in patients treated with T-DXd compared to T-DM1 [29].…”